EcoDrugPlus

Type-2 Angiotensin Ii Receptor-Like

Ensembl ID : ENSMMDG00005004247
Gene Symbol: LOC115366051
3 Cross references
185 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSMMDG00005005443
Gene Symbol: TYR
3 Cross references
198 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSMMDG00005021286
Gene Symbol: TYR
3 Cross references
202 Possible Orthologues:

Tyrosine Hydroxylase

Ensembl ID : ENSMMDG00005005585
Gene Symbol: TH
1 Cross references
187 Possible Orthologues:

Tyrosine Kinase 2

Ensembl ID : ENSMMDG00005001084
Gene Symbol: TYK2
3 Cross references
195 Possible Orthologues:

Tyrosine-Protein Kinase Jak2-Like

Ensembl ID : ENSMMDG00005007867
Gene Symbol: LOC115364763
3 Cross references
194 Possible Orthologues:

Tyrosine-Protein Kinase Lyn-Like

Ensembl ID : ENSMMDG00005003527
Gene Symbol: LOC115375513
3 Cross references
195 Possible Orthologues:

Tyrosine-Protein Kinase Fyna

Ensembl ID : ENSMMDG00005007339
Gene Symbol: LOC115354418
3 Cross references
191 Possible Orthologues:

Tyrosine-Protein Kinase Yes

Ensembl ID : ENSMMDG00005001905
Gene Symbol: LOC115374655
3 Cross references
206 Possible Orthologues:

Urotensin 2 Receptor

Ensembl ID : ENSMMDG00005014324
Gene Symbol: UTS2R
1 Cross references
97 Possible Orthologues:

Utrophin

Ensembl ID : ENSMMDG00005013388
Gene Symbol: UTRN
1 Cross references
270 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 3a

Ensembl ID : ENSMMDG00005013587
Gene Symbol: AKT3A
1 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).